Skip to main content

Table 1 Patient characteristics at baseline (ITT population)

From: Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency

  Prolastin
(n = 38)
Placebo
(n = 39)
p value
Age (years, mean ± SD) 54.7 ± 8.4 55.3 ± 9.8 0.749
Gender (n, male/female) 25/13 16/23 0.021
FEV1% predicted (mean ± SD) 46.3 ± 19.6 46.6 ± 21.0 0.873
PD15 (g/L, mean ± SD)a    
Whole lung 47.98 ± 19.07 45.48 ± 16.95 0.288
Apical region 63.36 ± 24.96 62.96 ± 19.77 0.625
Middle region 51.48 ± 18.35 48.35 ± 18.40 0.232
Basal region 38.61 ± 18.90 34.94 ± 15.44 0.182
MLD (g/L, mean ± SD)a 131.57 ± 21.99 131.68 ± 18.89 0.719
VI-910 (%, mean ± SD)a 44.43 ± 13.66 45.11 ± 12.02 0.509
VI-950 (%, mean ± SD)a 18.66 ± 10.97 19.77 ± 9.81 0.435
Lung weight (g, mean ± SD)a 956.40 ± 140.64 946.09 ± 224.12 0.750
Lung volume (L, mean ± SD)a 7.46 ± 1.60 7.27 ± 1.78 0.557
  1. SD, standard deviation; FEV1, forced expiratory volume in 1 second; PD15, 15th percentile lung density; MLD, mean lung density; VI-910, voxel index at a threshold of -910 (measured in %); VI-950, voxel index at a threshold of -950 (measured in %). aFor the CT densitometric analyses, the mITT population was used (n = 36, Prolastin; n = 35, placebo).